Litigation Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2017)

ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2017)

Docket		Date Filed	2017-07-12
Court	District Court, D. New Jersey	Date Terminated	2017-09-11
Cause	15:1126 Patent Infringement	Assigned To	Jose L. Linares
Jury Demand	None	Referred To	Joseph A. Dickson
Patents	9,211,253; 9,468,747; 9,561,177; 9,629,965
Link to Docket	External link to docket

Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-12	14		of United States Patent Numbers 9,211,253 (“‘253 patent”) and 9,468,747 (“747 patent”), Claim 10 of the… ‘253 patent and ‘747 patent, and Claim 29 of United States Patent No. 9,629,965 (“‘965 patent”).’ The…the ‘253 patent, Claims 3 and 33 of the ‘747 patent, Claims 5 and 27 of United States Patent No. 9,561,177…actuation.” (‘253 patent at 50:65—67; ‘747 patent at 53:42—44). Elsewhere, the ‘253 patent specification …9,561,177 (“177 patent”), and Claims 1 and 22 of the ‘965 patent. They have since resolved their dispute	External link to document

ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. Litigation Summary and Patent Analysis

Last updated: August 8, 2026

Adapt Pharma sued Teva in the U.S. District Court for the District of New Jersey after Teva filed an abbreviated new drug application seeking approval for a generic version of Narcan naloxone hydrochloride nasal spray. The case, No. 2:17-cv-05100-JLL-JAD, centered on U.S. Patent No. 9,629,965, which covered aspects of Adapt's intranasal naloxone delivery system.

The litigation was a Hatch-Waxman patent case involving a Paragraph IV certification. Its commercial significance was high because Teva's product targeted Narcan, the leading branded opioid-overdose reversal product. The dispute ultimately did not prevent Teva from entering the market with an FDA-approved generic naloxone nasal spray.

What drug and patent were involved in the Adapt Pharma v. Teva case?

The product was Narcan 4 mg nasal spray, whose active ingredient is naloxone hydrochloride. Adapt Pharma developed and commercialized the product in the United States. Emergent BioSolutions later acquired Adapt Pharma and its Narcan business.

The principal asserted patent was:

Patent	Title	Patent holder or plaintiff	Relevant product	Listed expiration
U.S. 9,629,965	Nasal delivery devices	Adapt Pharma Operations Limited and related entities	Narcan naloxone hydrochloride nasal spray	October 22, 2035, subject to applicable patent-term calculations

The patent claims addressed a nasal delivery device and related administration parameters for delivering naloxone. The litigation did not concern a biologic, so biosimilar provisions under the Biologics Price Competition and Innovation Act were not implicated.

The patent's commercial value arose from its relationship to the finished nasal spray product rather than from naloxone itself. Naloxone is an old active pharmaceutical ingredient, but the patented delivery configuration supported a convenient, ready-to-use nasal dosage form.

When did Adapt Pharma sue Teva, and what triggered the litigation?

Adapt filed the action in 2017 after receiving Teva's Paragraph IV notice. Teva's ANDA filing represented that the relevant Narcan patent was invalid, unenforceable, or would not be infringed by Teva's proposed generic product.

The lawsuit was filed within the 45-day period required to trigger the Hatch-Waxman litigation framework. Filing the action created an automatic FDA approval stay of up to 30 months under 21 U.S.C. § 355(j)(5)(B)(iii), unless the litigation was resolved earlier or the court otherwise modified the stay.

The case was assigned to District Judge Jose L. Linares and Magistrate Judge Joseph A. Dickson in the District of New Jersey:

Case element	Detail
Court	U.S. District Court for the District of New Jersey
Civil action	No. 2:17-cv-05100-JLL-JAD
Plaintiff	Adapt Pharma Operations Limited
Defendant	Teva Pharmaceuticals USA, Inc.
Legal framework	Hatch-Waxman Act
Regulatory trigger	Teva Paragraph IV ANDA certification
Product	Generic naloxone hydrochloride nasal spray
Patent at issue	U.S. 9,629,965

What were the principal legal issues in the Narcan patent litigation?

The case presented the standard ANDA issues of infringement, validity, and enforceability. The central commercial question was whether Teva could obtain FDA approval and launch a generic nasal naloxone product before the asserted patent's listed expiration.

The key issues included:

1. Whether Teva's proposed ANDA product infringed the asserted claims of the '965 patent.
2. Whether the asserted claims were invalid for obviousness under 35 U.S.C. § 103.
3. Whether the patent claims were adequately supported by the specification.
4. Whether Adapt could maintain patent protection over a nasal delivery system using an old active ingredient.
5. Whether any settlement or license would permit Teva to enter before the patent's expiration date.

The validity analysis was commercially important because the patent did not claim a new chemical entity. Teva's invalidity position therefore focused on whether the claimed nasal delivery arrangement would have been obvious to a skilled artisan based on prior-art naloxone formulations, nasal delivery systems, and dose-administration techniques.

Did Teva file a Paragraph IV challenge against Narcan?

Yes. Teva's ANDA certification challenged the relevant Narcan patent under Paragraph IV of the Hatch-Waxman Act.

A Paragraph IV certification is an assertion that a listed patent is invalid, unenforceable, or will not be infringed by the ANDA product. The certification gives the brand company a basis to sue for patent infringement before FDA approval. The litigation then determines whether the patent blocks approval and commercial launch.

The filing was not a regulatory challenge to naloxone's safety or effectiveness. It was a patent challenge directed at the legal scope of the listed patent.

What was the litigation outcome?

The case was resolved before Teva's generic product entered the U.S. market. Public docket records identify a negotiated resolution and termination of the action rather than a publicly reported trial judgment establishing a final infringement or invalidity ruling.

The resolution allowed Teva ultimately to commercialize an FDA-approved generic naloxone nasal spray. FDA approved Teva's generic naloxone hydrochloride nasal spray in 2021. Teva subsequently marketed the product as a lower-cost alternative to Narcan.

The public record does not establish that the court entered a final merits judgment invalidating the '965 patent. The commercial result was therefore different from a litigated invalidity judgment: Teva obtained market access through resolution of the patent dispute and subsequent regulatory approval.

When did Teva launch generic naloxone nasal spray?

FDA approved Teva's generic naloxone hydrochloride nasal spray in April 2021. Teva announced availability of the product at a lower price than branded Narcan.[1]

The approval demonstrated that the Adapt-Teva dispute did not maintain an effective monopoly over the U.S. naloxone nasal spray market through the full listed life of the '965 patent. The approval also expanded competition in a public-health market in which purchasers include pharmacies, first responders, government agencies, hospitals, and community organizations.

FDA approval did not itself decide the patent dispute. FDA reviews safety, efficacy, quality, and regulatory compliance. Patent clearance is addressed through the Hatch-Waxman certification and litigation process.

What was the Orange Book status of Narcan?

Narcan's Orange Book listing provided the regulatory basis for the Paragraph IV dispute. The listed patent covered the drug product's delivery system rather than naloxone's underlying chemical composition.

Orange Book listing information should be evaluated separately from patent validity. Listing a patent does not create a presumption that the patent is valid or infringed. It does, however, require an ANDA applicant to address the listed patent through one of the statutory certifications.

The relevant regulatory structure was:

Regulatory issue	Effect
Listed patent	Required Teva to submit a patent certification
Paragraph IV certification	Allowed Adapt to sue before FDA approval
Timely infringement action	Triggered the 30-month approval stay
Patent resolution or expiration	Removed the litigation-based approval barrier
FDA approval	Permitted commercial distribution subject to patent rights

The '965 patent's late expiration date reflected the value of formulation and device patenting. It did not mean that Teva would necessarily remain excluded until 2035. Settlement terms, claim scope, regulatory timing, patent litigation outcomes, and later patent listings can affect the practical launch date.

How strong was Adapt's Narcan patent estate?

Adapt's patent position was meaningful but concentrated. The primary dispute involved a delivery-system patent, not a broad composition-of-matter patent covering naloxone.

Strengths

The estate had several advantages:

• The patent was listed in the Orange Book for the branded nasal product.
• The patent had a long remaining term when the lawsuit was filed.
• The claims were tied to a commercially useful, ready-to-use nasal dosage form.
• The patent supported a pre-approval ANDA litigation strategy.
• The product's clinical and commercial success could support arguments concerning demand and unexpected results, depending on the evidence developed in the case.

Constraints

The estate also had structural limitations:

• Naloxone was an established active ingredient.
• Nasal delivery technology had substantial prior art.
• A device or formulation patent generally has narrower claim scope than a composition-of-matter patent.
• Teva could design around specific device or formulation limitations.
• A generic applicant could pursue approval after patent resolution even if the brand retained other intellectual-property rights.

The patent was therefore commercially important but not equivalent to a broad chemical monopoly. Its strength depended on claim construction, prior-art differences, the precise Teva device, and the evidentiary record concerning obviousness.

What formulation and method-of-use patents protected Narcan?

The Adapt-Teva case primarily concerned a nasal delivery system and formulation-related product characteristics. It was not a conventional method-of-use case involving a narrow patient subgroup or a disease indication.

Naloxone's therapeutic use in reversing opioid overdose was well established. The differentiated intellectual property was the delivery format:

• Intranasal administration.
• A prefilled, single-use device.
• A defined naloxone concentration and delivered volume.
• Administration without needles or assembly.
• Product configuration suitable for emergency use by non-specialists.

This distinction matters in generic competition. A drug can have limited protection for its active ingredient but meaningful protection for its dosage form, device, manufacturing process, or labeled use.

Did the case involve biosimilar risk?

No. Biosimilar risk was not relevant to this case.

Narcan is a small-molecule drug product regulated under the Federal Food, Drug, and Cosmetic Act. Teva pursued an ANDA, not a biosimilar application under the Public Health Service Act. The competitive threat was generic substitution, not biosimilar interchangeability.

The relevant risks were:

• Paragraph IV patent challenges.
• ANDA approval.
• Generic product design-around.
• Pharmacy substitution.
• Institutional purchasing competition.
• Price erosion after generic entry.

Which companies challenged or competed with Narcan?

Teva was the defendant in this action and became a generic competitor after FDA approval. Other companies also pursued naloxone products through different regulatory or commercial routes.

The competitive landscape included:

Company or product	Competitive pathway
Teva Pharmaceuticals	ANDA generic naloxone nasal spray
Emergent BioSolutions	Branded Narcan owner after acquisition of Adapt
Sandoz and other generic manufacturers	Potential or later ANDA competition, depending on product approvals
Kaléo	Evzio naloxone auto-injector, a competing delivery system
Amphastar Pharmaceuticals	Injectable and intranasal naloxone products

Competition was not limited to identical nasal sprays. Injectable naloxone, auto-injectors, over-the-counter products, and other nasal products competed for the same overdose-reversal demand.

What generic entry risks did Teva create for Narcan?

Teva's entry created the conventional first-generic risks:

1. Lower net pricing.
2. Pharmacy substitution.
3. Formulary pressure.
4. Reduced government and institutional procurement pricing.
5. Loss of exclusivity for a product with limited active-ingredient differentiation.
6. Increased negotiating leverage for public-health purchasers.
7. Reduced revenue per dose for the branded product.

Narcan's commercial exposure was unusual because the product operated in both prescription and public-health channels. Government programs, pharmacies, harm-reduction organizations, and first responders could prioritize affordability and supply availability over brand loyalty.

The impact of generic entry depended on the applicable state substitution rules, payer policies, purchasing contracts, product availability, and whether buyers viewed the generic as interchangeable in operational use.

What was the revenue exposure from the Teva challenge?

The Teva challenge exposed Narcan's U.S. nasal-spray revenue to price competition well before the '965 patent's nominal expiration. The exact exposure depended on sales channel and the terms of the parties' resolution.

Narcan was one of Emergent's most important commercial products. Emergent reported Narcan sales as a material component of its product revenue, with demand affected by opioid-overdose policy, government procurement, and public-health programs.[2]

Generic entry did not necessarily eliminate branded revenue. Brand products can retain sales through:

• Government contracts.
• Brand-specific procurement.
• Patient or institutional preference.
• Supply reliability.
• Marketing and distribution advantages.
• Product availability in over-the-counter or nonprescription channels.

The larger risk was net-price compression and loss of purchasing leverage. In a high-volume naloxone market, even moderate price erosion can materially affect revenue.

How did the Adapt-Teva case compare with other drug patent disputes?

The case differed from a typical blockbuster small-molecule case in three respects.

First, the active ingredient was old and inexpensive. The value resided in a delivery system designed for emergency use.

Second, the product's public-health importance created strong demand for lower-cost alternatives. Government and institutional purchasers had incentives to support generic availability.

Third, the regulatory and commercial barriers were separate. FDA approval of a generic product required a satisfactory ANDA review, while commercial launch required resolution of the patent dispute or other legal clearance.

The case is closer to device-and-formulation patent litigation than to litigation over a new molecular entity. That distinction affects both patent strength and the probability of design-around competition.

What is the current litigation significance of Adapt Pharma v. Teva?

The case illustrates how a listed formulation or device patent can delay generic approval without guaranteeing exclusion through patent expiration. The outcome also shows why commercial launch timing must be analyzed separately from the nominal patent term.

For diligence purposes, the material conclusions are:

• The asserted patent was U.S. 9,629,965.
• The case arose from Teva's Paragraph IV ANDA certification.
• The litigation was filed in the District of New Jersey in 2017.
• The dispute was resolved without a publicly reported final merits judgment invalidating the patent.
• Teva received FDA approval for generic naloxone nasal spray in 2021.
• Generic entry created price and share risk for Narcan.
• No biosimilar framework applied.
• The principal intellectual-property barrier was a nasal delivery system patent, not a new chemical entity patent.

Key Takeaways

• Adapt sued Teva over its proposed generic naloxone nasal spray under the Hatch-Waxman Act.
• U.S. Patent No. 9,629,965 was the principal patent at issue.
• The case involved a Paragraph IV certification and a statutory FDA approval stay.
• The patent protected aspects of Narcan's nasal delivery system, not naloxone as a new chemical entity.
• The litigation ended without a publicly reported final merits judgment invalidating the patent.
• FDA approved Teva's generic naloxone nasal spray in 2021.
• The commercial result was generic market entry before the '965 patent's listed 2035 expiration.
• The case created substantial pricing and procurement risk for Narcan.
• Biosimilar analysis is inapplicable because the product is a small-molecule drug regulated through an ANDA.
• The principal diligence issue is the practical effect of the settlement and any associated launch terms, not the nominal patent expiration alone.

FAQs About the Adapt Pharma and Teva Narcan Litigation

Was Adapt Pharma's Narcan patent invalidated in court?

No publicly reported final merits judgment in the case established that the asserted patent was invalid. The action was resolved before Teva's later FDA approval and commercial launch.

Did Teva launch the exact same Narcan product?

Teva launched a generic naloxone hydrochloride nasal spray approved through the ANDA pathway. The generic product competed with Narcan but was marketed as a generic product rather than under the Narcan brand.

Did the litigation concern naloxone's chemical composition?

No. The dispute concerned a nasal delivery system and related product limitations. Naloxone itself was not a newly patented chemical entity in this case.

Could other generic manufacturers enter the naloxone nasal-spray market?

Yes. Other manufacturers can seek FDA approval through ANDAs, subject to applicable patents, exclusivity, product requirements, and market conditions. The '965 patent alone would not necessarily prevent all future competition.

Did the case affect over-the-counter naloxone availability?

The case primarily concerned prescription Narcan and Teva's ANDA product. Later FDA and commercial decisions concerning nonprescription naloxone were separate regulatory developments and should not be treated as a direct judgment in the Adapt-Teva litigation.

References

1. U.S. Food and Drug Administration. (2021). FDA approves first generic naloxone hydrochloride nasal spray. https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-naloxone-hydrochloride-nasal-spray

2. Emergent BioSolutions, Inc. (2021). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/

3. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,629,965, Nasal delivery devices. https://patents.google.com/patent/US9629965

4. U.S. District Court for the District of New Jersey. (2017-2020). Adapt Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc., No. 2:17-cv-05100-JLL-JAD. Public docket record.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm